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Over the past decade, more than 12 genes have been identified to cause hereditary 
predispositions to hematologic malignancies. These syndromes are characterized by an 
increased risk to develop myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), 
or aplastic anemia (AA) at young ages, with various phenotypic features including peripheral 
cytopenias, immune dysfunction and skeletal defects. In 2013, Churpek et al. proposed a 
referral algorithm which consists of certain criteria for identifying leukemia patients who 
may benefit from genetic assessment for these hereditary syndromes. These criteria assess 
personal history of cytopenias, skin or nail abnormalities, immune deficiencies/atypical 
infections, and other associated clinical characteristics. The algorithm also assesses family 
history of leukemia and personal/family history of other malignancies.  
Our study aimed to assess the applicability of these criteria on an unselected 
population of adults with leukemia by retrospective chart review at The University of Texas 
M.D. Anderson Cancer Center. These patients presented for initial consultation from March 
1, 2014 to December 31, 2014. Six-hundred and eight individuals diagnosed with 
MDS/AML/AA were included in this study. Key demographic information was obtained 
from a clinical database maintained by the Department of Leukemia. The median age at 
diagnosis was 67 years, 387 (64%) were male, and at the time of data collection, 315 (51.8%) 
individuals were alive. Of the 608 individuals in this study, 334 (54.9%) were diagnosed with 
AML, 199 (32.7%) with MDS, 59 (9.7%) with MDS/MPD, and 16 (2.6%) with AA.  
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Regarding clinical/medical record documentation of referral criteria, three hundred 
and sixty-four (59.9%) individuals reported at least one first or second-degree relative with 
cancer. Thirty-one (5.1%) individuals reported a family history of leukemia, which was also 
the most consistently reported criteria in the medical record (n=580, 95.4%). Overall, 406 
individuals (66.8%) had insufficient documentation to determine whether any criteria were 
met. Two hundred and two (33.2%) individuals met at least one of the proposed criteria for 
genetic counseling referral; however, only nine received a referral (4.5%) to genetic 
counseling. Increased documentation of the presence or absence of phenotypic features 
associated with these hereditary syndromes is necessary to better assess the applicability of 
these criteria, and to ensure that individuals receive appropriate referral for cancer genetics 
risk assessment.  
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Introduction 
Leukemia is the tenth most common malignancy in the United States with an estimated 
60,140 new cases diagnosed in 2016 [1]. Familial occurrences of leukemia have been 
documented in the literature and first-degree relatives of individuals with leukemia carry an 
estimated 2.5-6 fold increased lifetime risk of leukemia depending on the type of leukemia in 
the family [6, 7]. In fact, approximately 10-20% of myelodysplastic syndromes (MDS), acute 
myeloid leukemia (AML), and aplastic anemia (AA) are related to newly-described 
hereditary predisposition syndromes [2-5]. 
Over the past decade, clinical investigations into families with multiple close relatives 
with leukemia have identified more than a dozen genes related to inherited predispositions to 
MDS and AML [3]. To date, genes associated with inherited MDS/AML syndromes include 
ANKRD26, ATG2B, CEBPA, DDX41, ETV6, GATA2, GSKIP, RUNX1, SH2B3, SRP72 and 
TP53. Additional predisposition genes  are also related to the inherited bone marrow failure 
syndromes (IBMFS), including Fanconi anemia (FA) caused by mutations in the Fanconi 
complementation groups (FANCA, BRCA2, PALB2, etc.) and dyskeratosis congenita (DC) 
caused by mutations in telomere maintenance genes (TERT, TERC) which have been 
associated with increased risks for AA, MDS, and AML. Together, these syndromes are 
characterized by significantly increased risk to develop MDS/AML/AA (30-100% lifetime 
risk) at younger ages (4-40 years old on average), with phenotypic characteristics including 
thrombocytopenia, other peripheral cytopenias, immune dysfunction, skeletal defects, and 
clinical bleeding in both adults and children [8, 9].  Additional phenotypes include primary 
lymphedema, deafness, cutaneous warts, low CD4/CD8 T cell ratio and mycobacterial 
infections [10-12], which can be seen in patients with germline GATA2 mutations.  
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Recently, research has revealed that previously described conditions like FA and DC 
have more variable phenotypic expressivity than previously described, with 25-40% of 
individuals with FA, and 10-25% of individuals with DC, having no physical characteristics 
suggestive of these conditions [13, 14]. Additionally, individuals with IBMFS who do not 
show classic physical characteristics are more likely to have delayed diagnosis of 
MDS/AML/AA, often in adulthood [13]. This variability makes IBMFS difficult to diagnose 
in individuals who do not display the characteristic phenotype. Timely diagnosis is critical 
for treatment of MDS/AML/AA, as patients with IBMFS and familial AML/MDS syndromes 
have poor outcomes from hematopoietic stem cell transplantation (HSCT) due to use of a 
related donor with the same germline mutation and/or increased toxicity from high-intensity 
transplant conditioning regimens [15-17]. 
The complications arising from HSCT transplantation from a related donor illustrates 
the importance of a thorough family history for these at risk individuals. In 2014, the 
American Society of Clinical Oncology (ASCO) published an expert opinion statement 
regarding the collection and use of family history in oncology assessments and suggested that 
the minimum family history obtained should include cancer history of first- and second-
degree relatives, including the type of primary cancer and age of diagnosis [14]. Although 
not all patients report an accurate family history, a study by Ziogas and Anton-Culver 
showed that most patient reports of family history are reliable, especially when reporting 
cancer history of first-degree relatives [18]. According to the ASCO statement, clinicians 
should be able to assess a family history to help determine if further evaluation for hereditary 
predisposition is warranted; however, a study by Sussner et al. revealed that only 1.7% of 
surveyed physicians felt they could accurately interpret a family history and make 
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appropriate recommendations [19, 20]. While previously considered exceedingly rare, the 
recent discovery of multiple hematologic malignancy predisposition syndromes requires 
increased clinical provider awareness. For optimal identification and appropriate referral of 
patients at risk of hereditary cancer syndromes, an accurate, detailed family history is critical 
to identify at-risk patients and families, as well as to help guide treatment and management.  
With the identification of these predisposition genes, researchers have sought to 
understand how frequently these germline mutations occur in patients with leukemia. 
DiNardo et al. identified germline mutations associated with a hereditary cancer syndrome in 
18% of patients with hematologic malignancies referred for genetic testing [2, 21]. Another 
study by Churpek et al. in 2016 illustrated a similar frequency of germline mutations (11-
24%) in patients with hematologic malignancies referred for genetic testing [2]. Notably, 
germline mutations in hematologic malignancies appear to show similar prevalence to 
germline mutations in solid tumors such as breast and colon cancers for which genetic risk 
assessment has become routine. 
In 2013, Churpek et al. proposed clinical detection and management criteria for 
patients and family members with familial MDS/AML/AA predisposition syndromes (Figure 
1). 
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Figure 1. Proposed Algorithm for identifying individuals for referral for comprehensive 
cancer risk assessment 
  
 
 
 
 
 
 
 
 
 
 
 
These criteria assess personal or family history of cytopenias, the presence of skin, 
nail, or limb abnormalities, unexplained liver disease, pulmonary fibrosis/alveolar 
proteinosis, lymphedema and immune deficiencies/atypical infections. Additionally, the 
algorithm assesses family history of acute lymphocytic leukemia (ALL)/MDS/AML/AA and 
other malignancies. Individuals meeting these criteria warrant referral to genetic counseling 
for comprehensive cancer risk assessment.  
To date, no studies have sought to evaluate the clinical applicability of these criteria 
to an unselected adult population of leukemia patients. We aim to assess the proposed 
algorithm against a large unselected cohort of patients with MDS/AML/AA to determine if 
Patient with MDS/AML/ALL
Yes
Referral for 
comprehensive 
cancer risk 
assessment
No
Family history should 
be updated every 5 
years
Family History of: 
-MDS/AML/ALL/AA 
-Early onset cancers of 
any type 
- Multiple close 
relatives with cancer 
Personal or family history of: 
- Low blood counts 
- Bleeding diathesis 
- Skin or nail abnormalities 
- Unexplained liver disease 
- Pulmonary fibrosis or  
  alveolar proteinosis 
- Limb anomalies 
- Lymphedema 
- Immune deficiencies/ 
  atypical infections 
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the characteristics needed to identify these patients for genetic counseling and risk 
assessment are reported in the medical record. Identifying these individuals is of utmost 
importance for personalized treatment strategies to maximize positive outcomes and 
minimize toxicity. 
 
Materials and Methods 
Patient Selection 
We identified 613 individuals seen as new patients in the Department of Leukemia at The 
University of Texas M.D. Anderson Cancer Center between March 1, 2014 to December 31, 
2014 with a diagnosis of MDS, AML, or AA.  Five individuals were excluded either due to 
age (<18 years old) at the time of their initial appointment, no leukemia diagnosis, or no 
medical records available for review, leaving 608 individuals for analysis. Medical history 
and pathology were obtained from a prospectively-maintained clinical database within the 
Department of Leukemia. Personal and family history, genetic testing performed, and referral 
criteria from the Churpek et al. algorithm were obtained by electronic medical record chart 
review. A somatic 28-gene panel was performed for all 608 patients and this information was 
used to assess for double mutant (dm) somatic mutation carriers.  To ensure adequate data 
capture, chart review procedure included assessment of the first five and last five leukemia 
department provider’s notes, and the leukemia department providers’ history and physical 
notes (H&P).   
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Statistical Analyses 
Patient demographics, clinicopathologic characteristics, and personal and family history 
variables were analyzed. We evaluated 608 patients with MDS/AML/AA for the proposed 
criteria (Figure 1) to determine if they met the proposed criteria, and whether eligible patients 
were recommended for cancer genetic risk assessment. The statistical significance between 
cohorts was determined using the chi-squared test and Fisher’s exact test for categorical 
variables, Wilcoxon rank sum test for continuous variables and nonparametric test for trend 
for ordered variables. All analyses were performed in STATA (v.13.1, College Station, TX).  
P-value <0.05 was set for statistical significance. This study was approved by the 
Institutional Review Board of The University of Texas M.D. Anderson Cancer Center and by 
the Committee for the Protection of Human Subjects of the University of Texas Health 
Science Center at Houston.  A waiver of informed consent was obtained. 
Results 
Demographics  
Clinical data and demographic information from 608 individuals diagnosed with 
AML/MDS/AA seen at our institution from March 1, 2014-December 31, 2014 are described 
in Table 1. 
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Table 1. Patient Demographics (n=608) 
 
Clinical Characteristics n (%) 
Median (IQR), age at diagnosis, years 
Male sex 
Vital status, living 
67 (56-73) 
387 (64) 
315 (51.8) 
Race/Ethnicity  
White 
Hispanic 
Black 
Unknown 
Asian 
Other 
478 (78.6) 
47 (7.7) 
38 (6.3) 
22 (3.6) 
18 (3) 
5 (0.8) 
Leukemia Diagnosis  
AML 
MDS 
MDS/MPD 
AA 
334 (54.9) 
199 (32.7) 
59 (9.7) 
16 (2.7) 
Personal History of Cancer  
None 
Prostate 
Breast 
Basal cell carcinoma 
Lymphoma 
Colon 
Other 
410 (67.4) 
37 (6.1) 
32 (5.3) 
32 (5.3) 
29 (4.7) 
12 (2.0) 
56 (9.2) 
Family History of Cancer*  
>1 FDR 
>1 SDR) 
None 
304 (50%) 
121 (19.9%) 
183 (30.1%) 
IQR: Inter Quartile Range 
AML: Acute Myeloid Leukemia; MDS: Myelodysplastic syndrome; MPD: Myeloproliferative disorder;  
AA: Aplastic anemia 
FDR: First-degree relative; SDR: Second-degree relative 
*Family history of cancer does not include family history of hematologic malignancies 
 
The median age at diagnosis was 67 years, 387 (64%) were male, and at the time of data 
collection, 315 (51.81%) individuals were still living. Four hundred and seventy-eight 
(78.6%) individuals in the cohort reported their ethnicity as non-Hispanic white. The 
majority of patients in our cohort had AML (n=334, 54.9%). Forty-three (7.1 %) individuals 
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had favorable MDS/AML cytogenetics, 278 (45.7%) had intermediate cytogenetics, and 174 
(28.6%) had unfavorable cytogenetics. One hundred and thirteen (18.6%) individuals had 
unknown cytogenetics results. 
  One hundred and ninety-eight (32.6%) individuals had a personal history of an 
additional primary cancer diagnosis prior to their leukemia diagnosis. Breast cancer, prostate 
cancer, and basal cell carcinoma of the skin were the three most common, comprising 51.1% 
of total prior primary malignancies reported. For analysis of somatic mutation status, 29 
(4.8%) individuals were found to have >2 somatic mutations in one of three genes known to 
be associated with hereditary hematologic malignancies, CEBPA, RUNX1 and GATA2.  
 
Criteria documentation and cancer genetics referral 
We evaluated the presence, absence, or unreported status of the referral criteria 
proposed by Churpek et al. among the 608 patients [Table 2].  
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Table 2. Documentation of the evaluated personal and family history criteria (n=608) 
 
Present 
n (%) 
Absent 
n (%) 
Unreported 
n (%) 
           Personal History Criteria 
Skin/nail abnormalities 39  (6.4) 524 (86.2) 45 (7.4) 
Anemia 19 (3.1) 259 (42.6) 330 (54.3) 
Thrombocytopenia 23 (3.8) 235 (38.7) 350 (57.5) 
Neutropenia 2 (0.3) 124 (20.4) 482 (79.3) 
Limb anomalies 7 (1.2) 70 (11.5) 531 (87.3) 
Pulmonary fibrosis/ alveolar proteinosis 22 (3.6) 7 (1.2) 579 (95.2) 
Unexplained liver disease 11 (1.8) 10 (1.7) 587 (96.5) 
Lymphedema 10 (1.6) 2 (0.3) 596 (98.1) 
Immune deficiencies/atypical infections 5 (0.8) 3 (0.5) 600 (98.7) 
            Family History Criteria 
Leukemia 31 (5.1) 549 (90.3) 28 (4.6) 
Cancer 364 (59.9) 216 (35.5) 28 (4.6) 
Other Cytopenias 11 (1.8) 10 (1.6) 587 (96.6) 
Thrombocytopenia 7 (1.2) 7 (1.2) 594 (97.6) 
 
Personal history of blood count abnormalities had an unreported frequency ranging 
from 54.3% (n=300) for anemia to 79.2% (n=482) for neutropenia. Physical characteristics 
(skin/nail abnormalities, unexplained liver disease, pulmonary fibrosis/alveolar proteinosis, 
limb anomalies, lymphedema, immune deficiencies/atypical infections) had the highest 
unreported rate. Prior history of immune deficiencies/atypical infections was unreported for 
98.7% (n=600) of individuals, while skin/nail abnormalities were usually reported (n=563, 
92.6%). Only 3.5% (n=21) of individuals had documentation for family history of other 
cytopenias. Similarly, only 2.4% (n=14) had family history of thrombocytopenia reported. 
The criterion with the highest reported documentation was family history of leukemia, noted 
in 95.4% (n=580) of individuals.  
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Family history of MDS/AML/AA  
Thirty-one (16.2%) individuals who met criteria reported a family history of MDS/AML/AA 
or acute lymphoblastic leukemia (ALL) (Table 3). 
Table 3. Family History of Leukemia (n=31) 
Cancer Family History 
FDR (n=17) 
n, % 
SDR (n=17) 
n, % 
AML 2 (6.5) 3 (9.7) 
MDS 3 (9.7) 1 (3.2) 
ALL 0 (0) 1 (3.2) 
AA 1 (3.2) 1 (3.2) 
Unknown leukemia 11 (35.5) 11 (35.5) 
 FDR, first-degree relative; SDR, second degree relative 
 AML: Acute Myeloid Leukemia; MDS: Myelodysplastic syndrome; MPD: Myeloproliferative disorder;  
 AA: Aplastic anemia 
 
 Two individuals reported 2 first-degree relatives with leukemia, and two individuals 
reported 2 second-degree relatives with leukemia, totaling 34 family members with reported 
hematologic malignancies in this cohort. The majority of reported family members with 
leukemia did not have a specified subtype of leukemia documented. Five (16.1%) had a first 
or second-degree relative with AML, four (12.9%) with MDS and two with AA (6.5%).  
 
Comparison between individuals who met criteria and those who could not be determined 
Overall, 406 (66.8%) individuals had insufficient documentation to determine whether any 
criteria were met. Two hundred and two (33.2%) individuals met at least one of the proposed 
criteria for genetic counseling referral. Due to insufficient documentation, no individuals 
were classified as not meeting criteria [Table 4].   
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Table 4. Comparison between patients who met criteria and could not be determined 
 
IQR: Inter Quartile Range 
AML: Acute Myeloid Leukemia; MDS: Myelodysplastic syndrome; MPD: Myeloproliferative disorder;  
AA: Aplastic anemia 
FDR: First-degree relative; SDR: Second-degree relative 
*Family history of cancer does not include family history of hematologic malignancies 
 
Characteristics 
Met Criteria (n=202) 
n (%) 
Could not be 
Determined (n=406) 
n (%) 
p-value 
Median (IQR) age at diagnosis, years 66 (56-73) 67 (56-73) 0.407 
Male sex 126 (62.4) 261 (64.3) 0.655 
Race   0.475 
White/Caucasian 
Unknown 
Black 
Asian 
Middle Eastern 
163 (80.7) 
21 (10.4) 
12 (5.9) 
6 (3) 
0 (0) 
315 (77.6) 
48 (11.8) 
26 (6.4) 
12 (3) 
5 (1.2) 
 
Diagnosis  0.250 
AML 
MDS 
MDS/MPD 
AA 
100 (49.5) 
76 (37.6) 
20 (9.9) 
6 (3) 
234 (57.6) 
123 (30.3) 
39 (9.6) 
10 (2.5) 
 
Personal History of Cancer    
Breast 
Prostate 
Lymphoma 
Basal Cell Carcinoma 
Other 
None 
18 (8.9) 
11(5.4) 
11(5.4) 
10 (5.0) 
27 (13.4) 
125 (61.9) 
14 (3.4) 
26 (6.4) 
18 (4.4) 
22 (5.4) 
41 (10.1) 
285 (70.3) 
0.006 
0.721 
0.553 
1.00 
Family History of Cancer    
BREAST    
FDR 
SDR 
30 
13 
39 
19 
0.058 
0.441 
LUNG    
FDR 
SDR 
25 
16 
35 
17 
0.151 
0.060 
PROSTATE    
FDR 
SDR 
24 
5 
27 
8 
0.042 
0.768 
COLON    
FDR 
SDR 
18 
7 
19 
15 
0.048 
1.000 
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There was no significant difference between patient’s age or sex at diagnosis and whether 
they met criteria (p=0.407, p=0.655). Seventy-seven (38.1%) individuals who met criteria had 
a prior malignancy. Prior history of breast cancer was associated with whether an individual 
met criteria for cancer genetics referral (p=0.006).  For our study, those who met criteria 
solely based on their personal history of breast cancer were diagnosed with breast cancer 
before age 45 as individuals diagnosed with breast cancer before age 45 meet National 
Comprehensive Cancer Network (NCCN) guidelines for genetic risk assessment.  
Five hundred and eighty (95.4%) patients had documentation of family history 
information in their medical record.  Three hundred and four (50%) individuals had at least 
one first-degree relative (FDR) with cancer documented in their medical record. One hundred 
and twenty-one individuals (19.9%) had at least one second-degree relative (SDR) with 
cancer documented in their medical record [Table 1]. Individuals that had a first- and second-
degree relative with the same malignancy were included in both calculations. The most 
commonly documented malignancies among FDRs were breast, lung, and prostate cancers, 
comprising 41.5% of total malignancies reported among FDRs (n=180). Additionally, having 
a FDR with prostate, colon, or ovarian cancer was a significant factor in whether or not an 
individual met criteria (p=0.042, p=0.048, p=0.000). The most commonly reported 
malignancies among SDRs were breast, lung, and colon cancers, comprising 50.9% of total 
malignancies reported in SDRs (n=87).  
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Referral to genetic counseling  
Of the 202 individuals that met at least one criteria for a cancer genetics referral according to 
the proposed algorithm, 166 (82.2%) met one criteria, 30 (14.8%) met 2, 5 (2.5%) met 3, and 
only one patient (0.5%) met 4 criteria [Table 5].  
Table 5. Referral criteria and subsequent referral to genetic counseling (n=202) 
 
 
Number of criteria met 
  1 2 3 4 
Referred to genetics (n=9) 4 (2.4) 4 (13.3) 1 (20) 0 (0) 
Not referred to genetics (n=193) 162 (97.6) 26 (86.7) 4 (80) 1 (100) 
p=0.002 
Only 9 patients (4.5%) who met criteria received a referral for clinical cancer genetics risk 
assessment The difference between number of criteria met and the likelihood for subsequent 
genetics referral was statistically significant (p=0.002) with those meeting more criteria being 
less likely to have been referred to genetics.   
 
Additional Criteria 
In addition to the criteria proposed by Churpek et al., we assessed the somatic mutation 
profile within this MDS/AML/AA cohort. In our cohort, 29 (4.8%) individuals were found to 
have >2 somatic mutations in three genes known to be associated with hereditary 
hematologic malignancies and tested within our current myeloid malignancy panel: CEBPA, 
RUNX1 and GATA2. Of 10 individuals with >2 CEBPA mutations, only four met one of the 
proposed Churpek et al. criteria. One patient with biallelic GATA2 mutations met two 
criteria. Of the 18 patients with >2 RUNX1 mutations, five met one of the referral criteria. 
We also assessed young age at MDS/AML/AA diagnosis, specifically individuals diagnosed 
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prior to age 40. In our cohort, 66 (10.85%) individuals were diagnosed ≤40 years. Of those, 
only 17 (%) met at least one of the Churpek criteria.  
 
Discussion 
We reviewed the medical records of 608 individuals to evaluate the criteria proposed 
by Churpek et al. to a large unselected adult leukemia population. The median age of 
diagnosis for our cohort (67 years) is consistent with the median age of diagnosis of leukemia 
within the general population (66 years [1]). Of note, in the two years since these individuals 
presented to The University of Texas M.D. Anderson Cancer Center, only 51.8% are alive, 
consistent with the poor long-term outcomes of MDS and AML in older patients, which have 
a 5-year survival rate of 26.9% [1]. The high mortality rate within a short time period 
illustrates the importance of prompt assessment and referral for genetic counseling and 
testing in this unique cancer population. Due to the otherwise low documentation of the 
majority of the referral criteria, individuals in this cohort met referral criteria based primarily 
on a personal/family history of malignancies. Those with a personal history of breast cancer, 
or a FDR diagnosed with prostate, colon or ovarian cancer, were more likely to meet criteria. 
This is consistent with current national guidelines that recommend genetic counseling 
referrals based on family history of these specific malignancies (i.e. BRCA1 and BRCA2 
evaluation). While not directly related to assessing for inherited leukemia syndromes, it is 
important to note that personal and family history of non-hematologic malignancies are 
referenced in the Churpek algorithm and should be assessed according to the ASCO 
guidelines, and followed up by appropriate cancer genetics evaluation (14).   
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The criteria proposed by Churpek et al. are the only published screening criteria to 
help identify individuals at increased risk for inherited leukemia predisposition syndromes. 
National society guidelines, like those from the National Comprehensive Cancer Network 
(NCCN), are lacking.  The absence of published guidelines and the relative novelty of these 
hereditary leukemia syndromes likely contributed to the poor documentation of these criteria 
items in the medical record. As illustrated in Table 5, the vast majority of patients in this 
cohort have multiple missing variables, including personal or family history characteristics 
such as thrombocytopenia, limb anomalies and immune deficiencies/atypical infections. This 
could partially be due to study design wherein information had to be stated unequivocally 
(i.e. documentation of pertinent negatives) to be considered present or absent from the 
medical record. Interestingly, the two most frequently reported criteria were family history of 
leukemia and personal history of skin/nail abnormalities.  Typically, family history and 
physical exam are integral to an initial medical consultation. Additionally, physical exam 
documentation is a required component of History & Physical medical record documentation 
and therefore may have contributed to the increased reporting of skin/nail abnormalities.  
Only 4.5% of patients who met at least one-referral criteria received a genetics 
referral. The trends seen in Table 6 illustrate that as the number of criteria increased, so did 
the percentage of patients referred.  The lack of cancer genetics referrals, coupled with the 
lack of documented personal and family history criteria makes it difficult to assess the true 
applicability of the criteria. 
One principal researcher reviewed all 608 charts and human error cannot be excluded 
as a possible limitation of this study.  Additionally, study design was a possible limitation to 
this study. Only the first five and last five leukemia providers’ notes and H&Ps were 
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examined for review. Some clinical documents, as well as charts from other specialties, were 
not reviewed. Criteria may have been documented in those charts but not obtained for this 
study. Racial demographics were skewed and not representative of the general population. 
Additionally, this study was solely comprised of individuals seen at The University of Texas 
M.D. Anderson Cancer Center, a tertiary referral center, and may not be representative of 
patients diagnosed with leukemia across the United States.  However, this did provide a large 
population of individuals with MDS/AML/AA from which to analyze.    
In addition to the criteria proposed by Churpek et al., we assessed the somatic 
mutation profile within this MDS/AML/AA cohort. Current literature suggests that about 7-
11% of somatic double mutant CEBPA (dmCEBPA) mutations are actually present in the 
germline [22, 23]. While the exact frequency of somatic RUNX1 mutations found to be 
germline is unknown, a two hit hypothesis for RUNX1 mutations has been proposed that 
could lead to the development of acute leukemia [24]. This is important considering 6 
individuals in this study with biallelic CEBPA mutations met no additional testing criteria, 
but have an increased risk for an inherited susceptibility. Based on previous estimates, it is 
likely that at least one individual in the cohort had a germline CEBPA mutation.  We propose 
that considering ≥2 somatic mutations in CEBPA, RUNX1 and GATA2 as an additional 
referral criterion may be warranted, as it would potentially increase the detection of 
individuals who otherwise have no additional indications for genetic risk assessment. 
Additionally, the presence of a variant allele frequency suggestive of germline inheritance 
(~50%) is an important question for future analysis regarding identifying patients at risk for 
germline mutations. We also assessed young age at MDS/AML/AA diagnosis, specifically 
individuals diagnosed prior to age 40 since individuals with IBMFS are at a significantly 
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increased risk to develop BMF before the age of 40 [16]. We propose that age dx <40 and/or 
the presence of >2 somatic mutations should be considered as additional criteria when 
assessing leukemia patients for referral for cancer genetics risk assessment.     
Suggestions to increase documentation include incorporating criteria assessment into 
the EMR, or obtaining information directly from patients via a short intake 
form/questionnaire. Further studies need to assess the applicability of these criteria and may 
benefit from including suggested additional criteria like molecular testing results and age of 
diagnosis prior to age 40. Further studies are needed to determine which combination of 
criteria yields the highest association with subsequent positive germline testing results.  
National guidelines for referral criteria for inherited leukemia susceptibility syndromes 
would likely increase detection of families with hereditary predispositions to hematologic 
malignancies.  
 
Conclusion 
One-third of individuals met at least one criteria for a cancer genetics referral based 
on the proposed algorithm, while the remainder could not be determined based on 
insufficient information present in the medical record. Ultimately, only nine individuals 
presenting during this nine-month interval meeting criteria received genetic counseling 
referrals. The presence or absence of proposed criteria must be documented in the medical 
record in order to assess clinical applicability in the leukemia population. Increased and 
timely detection of these families is important, as it would allow for more tailored transplant 
donor selection, treatment, anticipatory guidance counseling, and increased screening for at 
risk family members.  
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